Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells

Endocrine. 2017 Jul;57(1):179-182. doi: 10.1007/s12020-017-1235-3. Epub 2017 Jan 24.

Authors

Giovanni Tulipano¹, Lara Faggi², Stefan Schulz³, Maurizio Spinello⁴, Andrea Giustina^{2

5}

Affiliations

¹ Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. giovanni.tulipano@unibs.it.
² Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
³ Pharmacology and Toxicology, Jena University Germany, Jena, Germany.
⁴ Novartis Farma SpA, Origgio, Italy.
⁵ Endocrine Service, University of Brescia, Brescia, Italy.

PMID: 28120181
DOI: 10.1007/s12020-017-1235-3

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cell Line
Cell Line, Tumor
Dexamethasone / pharmacology
Dose-Response Relationship, Drug
Muscle Proteins / metabolism*
Muscle, Skeletal / drug effects
Muscle, Skeletal / metabolism*
Pituitary Gland / drug effects
Pituitary Gland / metabolism
Rats
Ribosomal Protein S6 Kinases, 70-kDa / drug effects*
Signal Transduction / drug effects*
Somatostatin / analogs & derivatives*
Somatostatin / pharmacology
TOR Serine-Threonine Kinases / metabolism

Substances

Muscle Proteins
Somatostatin
Dexamethasone
pasireotide
Ribosomal Protein S6 Kinases, 70-kDa
TOR Serine-Threonine Kinases